



25 October 2013

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclomedica
technegas
cyclopet

Cyclopharm Ltd
ABN 74 116 931 250
Bldg 75 Business & Technology Park
New Illawarra Road
Lucas Heights NSW 2234 Australia
POB 350 Menai Central NSW 2234
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

TechnegasPlus Generator Receives Japanese Regulatory Approval

Cyclopharm Limited (ASX: CYC) is pleased to announce that the company has received approval from the Japanese Ministry of Health to market the latest model of the TechnegasPlus Generator for clinical use.

Japan is the dominant market for diagnostic radiopharmaceuticals in the Asia Pacific region representing over 40% of the total market. Recent reports estimate that there are around 1,600 gamma cameras installed in about 1,120 nuclear medicine departments in Japan.

Despite Technegas being available in Japan since in the mid 1990's, the technology was predominantly used as a research tool with very little activity dedicated to clinical use.

Cyclopharm's Managing Director, Mr James McBrayer said, "prior to registering the latest model of the TechnegasPlus Generator we have been unable to effectively promote the clinical use of Technegas.

"Consequently, this approval will allow us to significantly expand the sales of TechnegasPlus into the Japanese market."

With commercial distribution negotiations currently underway, Management anticipates that meaningful revenues will commence during the first half of 2014.

For more information, please contact either:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411



Background

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700°C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Positron Emission Tomography (PET)

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease at a metabolic level. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed at a much earlier stage.